The reiteration of an Overweight rating by a major financial institution like Morgan Stanley indicates a positive outlook for Neurocrine Biosciences. The maintained price target of $130 suggests that the analyst believes the stock is still undervalued, which could lead to upward pressure on the stock price in the short term.